Form 4 for VSTM Verastem, Inc.
Accepted 2025-05-20 00:00:00 ET · period of report 2025-05-16 · accession 0001104659-25-051161 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-05-20 | 2025-05-20 | VSTM | Paterson Dan | Pres, CEO, Dir | S - Sale | $8.13 | -58.7K | 462.0K | -11% | -$477.0K | |
| M | 2025-05-20 | 2025-05-16 | VSTM | Paterson Dan | Pres, CEO, Dir | A - Grant | $0.00 | -175.0K | 370.7K | -32% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-05-20 | S | D | 58,677 | $8.13 | 461,982 | D | — | — | (F3) The sale reported on this Form 4 represents shares sold by the Reporting Person to satisfy statutory withholding requirements in connection with the vesting of restricted stock units. |
| 2 | Common | Common Stock | 2025-05-16 | A | D | 150,000 | $0.00 | 520,659 | D | — | — | (F2) The reported securities were subject to a performance RSU award that was granted on June 18, 2024. 150,000 RSUs vested on May 16, 2025, upon the Issuer's Compensation Committee of the board of directors determining the performance criteria of approval by the FDA of an NDA for the Company's combination therapy of avutometinib and defactinib for the treatment of low-grade serous ovarian cancer had occurred. |
| 3 | Common | Common Stock | 2025-05-16 | A | D | 25,000 | $0.00 | 370,659 | D | — | — | (F1) The reported securities were subject to a performance restricted stock units ("RSU") award that was granted on August 2, 2023. 25,000 RSUs vested on May 16, 2025, upon the Issuer's Compensation Committee of the board of directors determining the performance criteria of approval by the U.S. Food and Drug Administration (the "FDA") of a new drug application ("NDA") for a product which contains avutometinib in combination with defactinib had occurred. |